Two-drug regimens for HIV treatment

Area of Science:

• Infectious Diseases
• Virology
• Pharmacology

Background:

• Combination therapy with three antiretroviral agents has been standard for HIV-1 treatment since 1996.
• While three-drug regimens have improved, potential adverse effects remain a concern.
• Two-drug regimens offer a strategy to minimize lifelong antiretroviral drug exposure while maintaining viral suppression.

Purpose of the Study:

• To evaluate the efficacy and safety of two-drug antiretroviral regimens compared to traditional three-drug regimens for HIV-1 treatment.
• To assess the virological non-inferiority and adverse effect profiles of selected two-drug combinations.
• To highlight the evolving landscape of HIV-1 treatment options, including long-acting formulations.

Main Methods:

• Analysis of multiple large, randomized trials comparing two-drug versus three-drug antiretroviral regimens.
• Assessment of virological outcomes, including viral suppression and resistance emergence.
• Evaluation of safety, tolerability, metabolic profiles, and drug interactions associated with different two-drug regimens.

Main Results:

• Certain two-drug regimens have demonstrated virological non-inferiority to three-drug regimens.
• Adverse effect profiles of two-drug regimens reflect the known characteristics of their constituent drugs.
• Two-drug regimens are now incorporated into treatment guidelines and include the first long-acting option for HIV-1.

Conclusions:

• Two-drug antiretroviral regimens represent a viable and recommended strategy for HIV-1 treatment, offering reduced drug exposure and personalized care.
• Variations exist among two-drug regimens regarding risks of virological failure, resistance, tolerability, safety, and drug interactions.
• Current two-drug regimens are not recommended for individuals with chronic hepatitis B virus due to the absence of tenofovir.